News - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

80 to 104 of 339 results

Tris Pharma and FSC Labs enter Karbinal accord

04-09-2013

Drug delivery specialist Tris Pharma and fellow USA-based privately-held company FSC Laboratories have…

FSC LaboratoriesKarbinalLicensingNorth AmericaPharmaceuticalRespiratory and PulmonaryTris Pharma

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Meda acquires US respiratory company

02-09-2013

Swedish drugmaker Meda (STO:MEDAA) has signed an agreement to acquire the US development company Acton…

Acton PharmaceuticalsAerospan HFAFlunisolideMedaMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Actelion's Opsumit significantly reduced risk of morbidity/mortality events

29-08-2013

Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Rigel shares fall as asthma compound fails to meet primary endpoint

27-08-2013

Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Vectura foresees important catalysts in second half

13-08-2013

Shares of UK-based developer of inhaled therapies Vectura (LSE: VEC) rose 1.6% to 96 pence in mid-morning…

EuropeFinancialPharmaceuticalRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Bayer's PAH/CTEPH drug gets unanimous backing from FDA advisory panel

07-08-2013

In what was largely expected following this week's briefing papers from US Food and Drug Administration…

AdempasBayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

FDA advisory committee backs approval of Sanofi drug for OTC

01-08-2013

The US Food and Drug Administration's Nonprescription Drugs Advisory Committee (NDAC) voted 10 to six,…

Nasacort AQNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySanofiTeva Pharmaceutical Industries

Flutiform recommended for approval in Japan

01-08-2013

UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Two CHMP positives for Novartis

29-07-2013

There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

UK's NICE approves NHS funding for Novartis' Xolair for all eligible patients

24-07-2013

The UK's drugs watch dog the National Institute for Health and Care Excellence (NICE) has stipulated…

EuropeHealthcareNovartisPharmaceuticalRespiratory and PulmonaryXolair

Shares jump as Array BioPharma reports positive results for asthma drug

23-07-2013

US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate…

Array BioPharmaBiotechnologyNorth AmericaResearchRespiratory and Pulmonary

INTERVIEW: Verona Pharma's CEO Jan-Anders Karlsson on the company's hope for two

INTERVIEW: Verona Pharma's CEO Jan-Anders Karlsson on the company's hope for two "first-in-class" compounds for respiratory diseases

22-07-2013

With a clear passion for helping patients and a self-confessed need to know everything that is happening…

BiotechnologyBoardroomEuropePharmaceuticalRespiratory and PulmonaryVerona Pharma

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

US District Court issues final judgment in favor of Mylan in Brovana patent dispute

09-07-2013

US generics and specialty drugmaker Mylan (Nasdaq: MYL) revealed yesterday (July 8) that the US District…

BrovanaDainippon Sumitomo PharmaGenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalRespiratory and PulmonarySunovion

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

80 to 104 of 339 results

Back to top